@article{oai:niigata-u.repo.nii.ac.jp:00021283,
 author = {佐藤, 正之 and 村川, 英三},
 issue = {9},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Sep},
 note = {To diagnose DIC, we have always been looking for new parameters: e.g. fibrinogen and fibrin degradation products (FDP), antithrombinIII (ATIII), α_2 plasmin inhibitor (α_2PI), fibrinmonomer complex (FM) and D dimer (D-D). But these parameters have many problems: FDP can not distinguish between primary fibrinolysis and secondary fibrinolysis. With low plasma levels of ATIII and α_2PI, we can not see they are due to comsumption or due to reduced production. FM is not quantitative analysis. D-D which is specific for secondary fibrinolygis, is too sensitive to assess secondary fibrinolysis in DIC. We evaluated new molecular markers for the diagnosis of DIC in acute promyelocytic leukemia and other disorders: Thrombin antithrombin III complex (TAT) and plasmin・α_2 plasmin inhibitor complex (PIC). TAT and PIC were extremely elevated even though in probable DIC group with DIC scor<4. Abnormal findings of these parameters in probable DIC group seem to show hypercoagulability and fibrinolysis in this group. So plasma levels of TAT and PIC for the diagnosis of DIC should be established. With our data, plasma levels of both TAT≧7.5μg/l and PIC≧2.5μg/ml, three times of normal value, are valuable for the diagnosis of DIC. Recently the therapy of DIC has greatly advanced using synthetic protease inhibitors and ATIII concentrate.},
 pages = {632--638},
 title = {5) DIC : この十年間の歩み(新潟血栓止血研究会10周年記念特別例会記録)},
 volume = {105},
 year = {1991}
}